期刊
FRONTIERS IN ONCOLOGY
卷 12, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2022.826768
关键词
acute myeloid leukaemia; immunotherapy; biomarkers; checkpoint inhibition; T cell directed therapy
类别
This article provides an overview of recent advancements in immunotherapy for AML, focusing on biomarkers of response. The topics covered include antibody drug conjugates, BiTEs, DARTs, checkpoint inhibitors, cellular therapy, and the development of predictive biomarkers for response in each class.
Immunotherapy has without question revolutionized the treatment of both hematologic and solid malignancies. Over the last several years novel strategies are being developed to incorporate these groundbreaking therapies into the care of patients with AML. Here we present an overview of the recent developments in immunotherapy for AML with a focus on biomarkers of response. Topics reviewed include antibody drug conjugates, BiTEs, DARTs, checkpoint inhibitors, and cellular therapy as well as the development of biomarkers predictive of response in each class.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据